Delivery Order SPE2DB22D9239-SPE2DB25FDJ80

Award Date 6/3/25
Potential Completion Date 6/4/25
Potential Value $43K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 order is for the delivery of XTANDI 40 MG CAPSULE 120S, with a completion date of May 20, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This single-award...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,868.10 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, and is not associated with any set-aside program. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $33,923.76, is for the delivery of XTANDI 40 MG CAPSULE 120S over the period of September 10, 2024 to September 10, 2024. DMS Pharmaceutical Group Inc. holds a larger single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, with a performance period ending on June 12, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 firm fixed-price contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The order has a completion date of June 14, 2024. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
This is a Firm Fixed Price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,934.05 order is for the delivery of the prescription drug XTANDI 40 MG CAPSULE 120S, with a completion date of June 25, 2024. The order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the...
This is a $43,113.50 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for 4565020504 - XTANDI 40 MG CAPSULE 120S, with a completion date of June 28, 2024. The contract is part of a larger $499,999,999 indefinite delivery contract (IDC) awarded to DMS Pharmaceutical Group by the DLA under the SPE2DB program, which allows the DLA...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $77,604.30, is for the delivery of XTANDI 40 MG CAPSULE 120S to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA, valued up to $499,999,999, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $17,245.40 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $34,490.80 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The contract has a completion date of February 29, 2024. DMS Pharmaceutical Group holds an indefinite delivery contract (IDC) with the DLA, contract 4600082013 under the SPE2DB program, valued at up to...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDJ80
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, with a performance period ending on June 4, 2025.

DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting medical supply needs of military health facilities worldwide. The contract does not have a set-aside designation.

Generated 9/2/25, 9:47 AM